Research analysts at StockNews.com initiated coverage on shares of BSQUARE (NASDAQ:BSQR – Get Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the software maker’s stock.
BSQUARE Price Performance
BSQR opened at $1.23 on Tuesday. The company has a market capitalization of $24.59 million, a price-to-earnings ratio of -8.79 and a beta of 1.30. The firm’s fifty day moving average price is $1.23 and its two-hundred day moving average price is $1.19. BSQUARE has a 1 year low of $1.00 and a 1 year high of $1.50.
Hedge Funds Weigh In On BSQUARE
An institutional investor recently bought a new position in BSQUARE stock. Virtu Financial LLC purchased a new position in BSQUARE Co. (NASDAQ:BSQR – Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 29,469 shares of the software maker’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.15% of BSQUARE as of its most recent filing with the Securities and Exchange Commission. 14.91% of the stock is currently owned by institutional investors and hedge funds.
About BSQUARE
BSQUARE Corporation develops and deploys technologies for the makers and operators of connected devices in North America, Europe, and Asia. It operates through two segments, Partner Solutions and Edge to Cloud. The company offers software that connect devices to create intelligent systems; and embedded operating system software and services for makers of connected and intelligent devices, such as point-of-sale terminals, kiosks, tablets and handheld data collection devices, smart vending machines, ATMs, essential equipment in buildings and facilities environments, digital signs, and healthcare and entertainment devices.
Read More
- Five stocks we like better than BSQUARE
- Is It Time To Take Another Bite Of Chewy, Inc?
- GreenPower Motor Company Shifts Into High Gear
- Is the Microsoft Deal Driving Applied Optoelectronics 300% Gain?
- Can Unity Software Sustain The Momentum?
- Nvidia Invested $50 million into This AI Drug Discovery Biotech
Receive News & Ratings for BSQUARE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BSQUARE and related companies with MarketBeat.com's FREE daily email newsletter.
